Scoggin Management’s Kronos Bio KRON Stock Holding History

Scoggin Management’s Portfolio KRON Stock Details KRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-155,232	Closed	-$267K	–	70
2023 Q2	$267K	Buy	+155,232	New	+$246K	0.17%	41

Other funds holding KRON

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Scoggin Management's KRON Position: Q3 2023 in Review

Scoggin Management sold out of Kronos Bio (KRON) in Q3 2023, closing a stake of 155,232 shares — an estimated $267K sold.

Scoggin Management first reported a position in KRON in Q2 2023 and held it in 1 quarter. The position peaked at $267K in Q2 2023. 63 funds tracked by Wall St. Rank hold KRON as of Q3 2023.

Scoggin Management reported no remaining Kronos Bio position as of Q3 2023 after selling out during the quarter.
Scoggin Management sold 155,232 Kronos Bio shares in Q3 2023, an estimated $267K.
Scoggin Management first reported a position in Kronos Bio in Q2 2023 and held it in 1 quarter.
Scoggin Management's Kronos Bio position peaked at $267K in Q2 2023.
63 funds tracked by Wall St. Rank held Kronos Bio as of Q3 2023.

Based on Scoggin Management's 13F filing for Q3 2023, filed 14 Nov 2023.